Marco Trevisan

2.3k total citations
45 papers, 1.3k citations indexed

About

Marco Trevisan is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Marco Trevisan has authored 45 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cardiology and Cardiovascular Medicine, 17 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Marco Trevisan's work include Atrial Fibrillation Management and Outcomes (11 papers), Potassium and Related Disorders (7 papers) and Heart Failure Treatment and Management (6 papers). Marco Trevisan is often cited by papers focused on Atrial Fibrillation Management and Outcomes (11 papers), Potassium and Related Disorders (7 papers) and Heart Failure Treatment and Management (6 papers). Marco Trevisan collaborates with scholars based in Sweden, United States and Italy. Marco Trevisan's co-authors include Juan Jesús Carrero, Bengt Lindholm, Marie Evans, Hong Xu, Lars H. Lund, Peter Bárány, Rino Bellocco, Friedo W. Dekker, Edouard L. Fu and Tomas Jernberg and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Marco Trevisan

41 papers receiving 1.3k citations

Peers

Countries citing papers authored by Marco Trevisan

Since Specialization

Citations

This map shows the geographic impact of Marco Trevisan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Trevisan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Trevisan more than expected).

Fields of papers citing papers by Marco Trevisan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Trevisan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Trevisan. The network helps show where Marco Trevisan may publish in the future.

Co-authorship network of co-authors of Marco Trevisan

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Trevisan. A scholar is included among the top collaborators of Marco Trevisan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Trevisan. Marco Trevisan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer 2024 ·European Journal of Cancer ·Guilhem Roubaud, Gerhardt Attard, Martin Boegemann, David Olmos, Marco Trevisan, Laurent Antoni, (unknown), (unknown), Suzy Van Sanden, Mahmoud Hashim, Stephen Palmer, Kim Chi	2
2	Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer 2024 ·Advances in Therapy ·Maria De Santis, (unknown), Paul Robinson, (unknown), (unknown), Suzy Van Sanden, Mahmoud Hashim, Marco Trevisan, Caitlin Daly, (unknown), (unknown), (unknown), Bart Heeg, Elena Verzoni	0
3	Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation 2022 ·EP Europace ·(unknown), (unknown), (unknown), Serge A. Trines, Rolf H. H. Groenwold, Olaf M. Dekkers, Marco Trevisan, Juan Jesús Carrero, Merel van Diepen, Friedo W. Dekker, Ype de Jong	21
4	Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care 2021 ·European Journal of Heart Failure ·Marco Trevisan, Edouard L. Fu, Yang Xu, Gianluigi Savarese, Friedo W. Dekker, Lars H. Lund, Catherine M. Clase, Arvid Sjölander, Juan Jesús Carrero	43
5	Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction 2020 ·European Heart Journal - Cardiovascular Pharmacotherapy ·Marco Trevisan, Edouard L. Fu, Karolina Szummer, Anna Norhammar, Pia Lundman, Christoph Wanner, Arvid Sjölander, Tomas Jernberg, Juan Jesús Carrero	30
6	Acceleration of Kidney Function Decline After Incident Hospitalization with Cardiovascular Disease: The Stockholm CREAtinine Measurements (SCREAM) Project 2020 ·European Journal of Heart Failure ·Junichi Ishigami, Marco Trevisan, Lars H. Lund, Tomas Jernberg, Josef Coresh, Kunihiro Matsushita, Juan Jesús Carrero	21
7	Bisphosphonate utilization across the spectrum of eGFR 2020 ·Archives of Osteoporosis ·Silvia Titan, (unknown), Yingying Sang, Alex R. Chang, Marie Evans, Marco Trevisan, Andrew S. Levey, Morgan E. Grams, Lesley A. Inker, Juan Jesús Carrero	3
8	Kidney function and the risk of heart failure in patients with new-onset atrial fibrillation 2020 ·International Journal of Cardiology ·Juan Jesús Carrero, Marco Trevisan, Marie Evans, Emma Svennberg, Karolina Szummer	5
9	Kidney Dysfunction and the Risk of Developing Aortic Stenosis 2019 ·Journal of the American College of Cardiology ·(unknown), Magnus Bäck, (unknown), Marco Trevisan, Rino Bellocco, Marie Evans, Bengt Lindholm, Karolina Szummer, Juan Jesús Carrero	62
10	Short- and long-term outcomes after incident pneumonia in adults with chronic kidney disease: a time-dependent analysis from the Stockholm CREAtinine Measurement project 2019 ·Nephrology Dialysis Transplantation ·Guobin Su, Marco Trevisan, Junichi Ishigami, Kunihiro Matsushita, Cecilia Stålsby Lundborg, Juan Jesús Carrero	12
11	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction 2018 ·JACC Heart Failure ·Gianluigi Savarese, Hong Xu, Marco Trevisan, Ulf Dahlström, Patrick Rossignol, Bertram Pitt, Lars H. Lund, Juan Jesús Carrero	63
12	Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction 2018 ·American Heart Journal ·Hong Xu, (unknown), Karolina Szummer, Marco Trevisan, Csaba P. Kövesdy, Tomas Jernberg, Juan Jesús Carrero	10
13	Incidence, Predictors and Clinical Management of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists 2018 ·European Journal of Heart Failure ·Marco Trevisan, (unknown), Hairong Xu, Marie Evans, Bengt Lindholm, Rino Bellocco, Peter Bárány, Tomas Jernberg, Lars H. Lund, Juan Jesús Carrero	121
14	Increasing Agrin Function Antagonizes Muscle Atrophy and Motor Impairment in Spinal Muscular Atrophy 2018 ·Frontiers in Cellular Neuroscience ·Marina Boido, (unknown), Valeria Valsecchi, Marco Trevisan, Ugo Ala, Markus A. Rüegg, Stefan Hettwer, Alessandro Vercelli	42
15	Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease 2017 ·Gastroenterology ·Derk C.F. Klatte, Alessandro Gasparini, Hong Xu, (unknown), Marco Trevisan, Anna L.V. Johansson, Björn Wettermark, Johan Ärnlöv, Cynthia Janmaat, Bengt Lindholm, Friedo W. Dekker, Josef Coresh, Morgan E. Grams, Juan Jesús Carrero	116
16	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial 2017 ·Journal of the American College of Cardiology ·Raffaele De Caterina, Giulia Renda, Anthony Carnicelli, Francesco Nordio, Marco Trevisan, Michele Mercuri, Christian T. Ruff, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano	88
17	Abstract 17513: Edoxaban for the Prevention of Thromboembolism in Patients With Bioprosthetic Valves in ENGAGE AF-TIMI 48 2016 ·Circulation ·Anthony Carnicelli, Raffaele De Caterina, Jonathan L. Halperin, Giulia Renda, Christian T. Ruff, Marco Trevisan, Francesco Nordio, Michele Mercuri, Elliot M. Antman, Robert P. Giugliano	2
18	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial 2016 ·European Heart Journal ·Christina Fanola, Robert P. Giugliano, Christian T. Ruff, Marco Trevisan, Francesco Nordio, Michele Mercuri, Elliott M. Antman, Eugene Braunwald	37
19	Measurement variability of plasma β-sitosterol and campesterol, two new biomarkers for cancer prevention 2001 ·European Journal of Cancer Prevention ·(unknown), Atif B. Awad, Carol S. Fink, (unknown), Marco Trevisan, Paola Muti	18
20	Oxidative Stress and Lung Function 1997 ·American Journal of Epidemiology ·Holger J. Schünemann, Paola Muti, Jo L. Freudenheim, David T. Armstrong, Richard W. Browne, Robert A. Klocke, Marco Trevisan	97

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact